Compare BRT & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRT | PROF |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.2M | 263.8M |
| IPO Year | 1994 | 2017 |
| Metric | BRT | PROF |
|---|---|---|
| Price | $14.62 | $6.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.75 | $12.00 |
| AVG Volume (30 Days) | 37.2K | ★ 137.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | $16,098,000.00 |
| Revenue This Year | $3.82 | $92.40 |
| Revenue Next Year | $5.35 | $64.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.46 | ★ 50.73 |
| 52 Week Low | $13.18 | $3.92 |
| 52 Week High | $16.69 | $8.95 |
| Indicator | BRT | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 43.59 |
| Support Level | $14.20 | $6.24 |
| Resistance Level | $14.94 | $7.03 |
| Average True Range (ATR) | 0.38 | 0.49 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 61.18 | 13.57 |
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.